Evelo Biosciences holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 6.81, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Evelo Biosciences will likely underperform. Use Evelo Biosciences mean deviation, jensen alpha, as well as the relationship between the Jensen Alpha and rate of daily change , to analyze future returns on Evelo Biosciences.
Risk-Adjusted Performance
Fair
Weak
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Evelo Biosciences are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Evelo Biosciences displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow
69.8 M
Total Cashflows From Investing Activities
-622 K
Evelo
Evelo Biosciences Relative Risk vs. Return Landscape
If you would invest 0.02 in Evelo Biosciences on October 15, 2025 and sell it today you would earn a total of 0.03 from holding Evelo Biosciences or generate 150.0% return on investment over 90 days. Evelo Biosciences is currently generating 7.2951% in daily expected returns and assumes 55.7343% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Evelo, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Given the investment horizon of 90 days Evelo Biosciences is expected to generate 78.81 times more return on investment than the market. However, the company is 78.81 times more volatile than its market benchmark. It trades about 0.13 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.17 per unit of risk.
Evelo Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evelo Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Evelo Biosciences, and traders can use it to determine the average amount a Evelo Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1309
High Returns
Best Equity
EVLO
Good Returns
Average Returns
Small Returns
Cash
Small Risk
Average Risk
High Risk
Huge Risk
Negative Returns
Based on monthly moving average Evelo Biosciences is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evelo Biosciences by adding it to a well-diversified portfolio.
Evelo Biosciences Fundamentals Growth
Evelo Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Evelo Biosciences, and Evelo Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evelo Pink Sheet performance.
By examining Evelo Biosciences' fundamental ratios, stakeholders can obtain critical insights into Evelo Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Evelo Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Evelo Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.
Things to note about Evelo Biosciences performance evaluation
Checking the ongoing alerts about Evelo Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Evelo Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Evelo Biosciences is way too risky over 90 days horizon
Evelo Biosciences has some characteristics of a very speculative penny stock
Evelo Biosciences appears to be risky and price may revert if volatility continues
Evelo Biosciences has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (114.53 M) with profit before overhead, payroll, taxes, and interest of 0.
Evelo Biosciences currently holds about 92.01 M in cash with (101.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 83.0% of the company shares are held by institutions such as insurance companies
Evaluating Evelo Biosciences' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Evelo Biosciences' pink sheet performance include:
Analyzing Evelo Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evelo Biosciences' stock is overvalued or undervalued compared to its peers.
Examining Evelo Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Evelo Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evelo Biosciences' management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Evelo Biosciences' pink sheet. These opinions can provide insight into Evelo Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Evelo Biosciences' pink sheet performance is not an exact science, and many factors can impact Evelo Biosciences' pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Other Information on Investing in Evelo Pink Sheet
Evelo Biosciences financial ratios help investors to determine whether Evelo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evelo with respect to the benefits of owning Evelo Biosciences security.